Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gish gets US nod for heparin-coated cardioplegia technology:

This article was originally published in Clinica

Executive Summary

Gish Biomedical has completed its line of heparin-coated Vision products for heart-lung bypass surgery, after gaining US FDA 510(k) clearance for its blood cardioplegia (VBC) system. The product incorporates a heat exchanger design that offers greater than 90% heat exchange efficiency at 250ml/min blood flow. It also includes an integrated bubble trap. Gish, a subsidiary of Wilmington, Massachusetts-based CardioTech International, believes that the potential market for heart-lung bypass products could reach $200m annually. The entire heart-lung products market is estimated at $500m annually.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts